Neovacs’ interferon-alpha kinoid vaccine for type 1 diabetes will enter a preclinical trial under a collaboration agreement with researchers at the Cochin Hospital in Paris. The vaccine, which was studied as a lupus treatment in phase 1 and 2 trials, produces polyclonal neutralizing antibodies to interrupt IFN-alpha.
Healio (free registration)/Endocrine Today (10/22)
News provided by DiabetesPro SmartBrief in conjunction with the American Diabetes Association.